Last reviewed · How we verify
Mirapex
At a glance
| Generic name | Mirapex |
|---|---|
| Also known as | Pramipexole |
| Sponsor | Rajesh Pahwa, MD |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy (PHASE4)
- Single-dose,First-in-human of KLA478 (PHASE1)
- Pramipexole and the Risk of Serious Adverse Events
- Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV (PHASE2)
- Stanford RAD-AT Study (Research on Anxiety and Depression - Anhedonia Treatment)
- A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. (PHASE3)
- Phase III Long-Term Extension Study With Dexpramipexole (PHASE3)
- A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mirapex CI brief — competitive landscape report
- Mirapex updates RSS · CI watch RSS
- Rajesh Pahwa, MD portfolio CI